Celltrion USA Appoints Thomas Nusbickel as Chief Commercial Officer
Celltrion USA Appoints Thomas Nusbickel as Chief Commercial Officer
- Seasoned commercial operations executive brings three decades of global biopharmaceutical industry experience to Celltrion USA’s leadership team
February 06, 2023, CHICAGO, IL –Celltrion USA, a global leader in expanding access to innovative biologics, today announced the appointment of Thomas Nusbickel as Chief Commercial Officer. Mr. Nusbickel will oversee the company’s commercial operations and play a key role in expanding access to Celltrion’s rapidly growing portfolio of innovative biologics in the United States.
Mr. Nusbickel’s commercial experience includes more than 30 years in the biopharmaceutical industry, with extensive experience launching and expanding access to pharmaceuticals across multiple therapeutic areas including oncology and immunology. Mr. Nusbickel brings deep experience in the biosimilar space from previous roles, where he championed affordable access to biosimilars as Vice President Access and Government Affairs at Coherus BioSciences and built an industry-leading account sales and market access team to support product launches as Head of U.S. Market Access for Biosimilars at Pfizer company. He also brings more than 20 years of experience in value access and advocacy and global marketing serving in senior executive roles at Amgen. Mr. Nusbickel holds a master’s degree in business administration from Pepperdine University and a bachelor’s degree in biology from Eckerd College.
“I’m honored to take on this new role as chief commercial officer of Celltrion USA and join a mission-driven company delivering innovative biologics to improve care for U.S. patients,” said Mr. Nusbickel. “I look forward to leveraging my experience in the biopharmaceutical field to build on a solid pathway to deliver long-term growth for the company. Together with my colleagues, we will bring a growing pipeline of innovative treatments including Vegzelma® (biosimilar bevacizumab), Yuflyma™(biosimilar adalimumab) and a novel subcutaneous formulation of infliximab.”
“This year will be a landmark year for biosimilars and Celltrion USA is prepared for an exciting future ahead as we continue to drive strategic growth to address unmet medical needs for patients in the United States,” said Hyoung Ki Kim, Vice-Chairman & CEO at Celltrion Healthcare.. “We are thrilled to welcome Thomas Nusbickel to our leadership team at this critical time.”
Notes to Editors:
About Celltrion Healthcare
Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed, and built to comply with the US FDA Current Good Manufacturing Practice (cGMP) and the EU GMP guidelines. Celltrion Healthcare endeavors to offer high-quality, cost-effective solutions through an extensive global network that spans more than 110 different countries. For more information, please visit: https://www.celltrionhealthcare.com/en-us.
About Celltrion USA
Celltrion USA is Celltrion Healthcare’s U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion currently has four biosimilars approved by the U.S. FDA: Inflectra® (infliximab), Truxima® (rituximab), Herzuma® (trastuzumab), and Vegzelma® (bevacizumab). Celltrion USA will continue to leverage Celltrion Healthcare’s unique heritage in biotechnology, supply chain excellence, and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients.
FORWARD-LOOKING STATEMENT
Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion/Celltrion Healthcare that may constitute forward-looking statements, under pertinent securities laws.
These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.
In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion/Celltrion Healthcare's management, of which many are beyond its control.
Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.
Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this presentation are based upon what management of Celltrion/Celltrion Healthcare believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion/Celltrion Healthcare undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.